Funds and ETFs Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 15:59:44 24/05/2024 BST 5-day change 1st Jan Change
1,926 DKK -4.86% Intraday chart for Genmab A/S -5.61% -10.60%

ETFs positioned on Genmab A/S

Name Weight AuM 1st Jan change Investor Rating
3.64% 200 M€ +18.18%
1.28% 48 M€ +9.74%
1.01% 85 M€ +0.47%
0.75% 17 M€ +7.15% -
0.56% 727 M€ +8.98%
0.49% 88 M€ +10.37% -
0.45% 25 M€ +3.57% -
0.33% 6 M€ -.--% -
0.33% 4 M€ -.--% -
0.32% 36 M€ +2.94% -
0.31% 6 M€ -.--%
0.29% 2 M€ +9.19% -
0.29% 2 M€ -.--% -
0.24% 29 M€ +8.37% -
0.20% 7 M€ +5.87% -
0.19% 20 M€ +1.25% -
0.14% 3,859 M€ +18.82% -
0.14% 469 M€ -2.05%
0.14% 10 M€ -3.35% -
0.09% 276 M€ +11.40% -
0.08% 264 M€ -.--% -
0.08% 187 M€ +11.45% -
0.08% 477 M€ +12.73%
0.07% 7 M€ +0.11% -
0.06% 0 M€ 0.00% -
0.04% 283 M€ +21.92%
0.04% 206 M€ -.--%
0.04% 1,166 M€ +0.26% -
0.04% 607 M€ +0.05% -
0.04% 23 M€ -.--% -
0.04% 786 M€ -.--%
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,926 DKK
Average target price
2,466 DKK
Spread / Average Target
+27.99%
Consensus
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. Funds and ETFs Genmab A/S